Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss risk factors guiding frontline therapy decisions in EGFR-mutated NSCLC.
Back
Shifting Clinical Benchmarks in EGFR-Mutated Non–Small Cell Lung Cancer
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss evolving frontline treatments and sequencing considerations in EGFR-mutated NSCLC.
Shifting Clinical Benchmarks in EGFR-Mutated Non–Small Cell Lung Cancer
Episodes
All
All
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss sequencing strategies in advanced EGFR-mutated NSCLC.
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss evolving frontline treatment options in EGFR-mutated non–small cell lung cancer.
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss resistance mechanisms in EGFR-mutated NSCLC.
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss clinical experience with antibody-drug conjugates in EGFR-mutated NSCLC.
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss remaining evidence gaps in EGFR-mutated NSCLC care.
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss ongoing research shaping EGFR-mutated NSCLC care.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5